GeneDx Reports Strong Q4 & Full Year 2025 Results, Exceeding Guidance and Reaffirming Positive 2026 Outlook

summarizeSummary

GeneDx Holdings Corp. delivered a robust financial performance for both the fourth quarter and full year 2025, consistently meeting or exceeding its own guidance across key metrics. The company demonstrated significant growth in its core exome and genome testing business, with full-year revenue increasing by 41% and exome/genome test revenue growing by 54% year-over-year. Notably, adjusted net income for the full year 2025 saw a substantial improvement to $41.8 million, up from $9.4 million in the prior year, signaling a positive trajectory towards profitability on an adjusted basis. The reaffirmation of strong 2026 guidance, including continued revenue and volume growth and positive adjusted net income, provides a clear and optimistic outlook for investors. Additionally, the company raised $21.1 million through an At-The-Market offering in Q4 2025, bolstering its cash position.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Performance

  Reported Q4 2025 revenues of $121.0 million (up 27% YoY) and full year 2025 revenues of $427.5 million (up 41% YoY). Exome and genome test revenue grew 32% in Q4 and 54% for the full year.

• Met or Exceeded All Key 2025 Guidance Metrics

  The company met its full year 2025 guidance for total revenue, exome and genome revenue growth, exome and genome volume growth, and adjusted gross margin.

• Significant Improvement in Adjusted Net Income

  Full year 2025 adjusted net income reached $41.8 million, a substantial increase from $9.4 million in full year 2024, indicating improved operational efficiency and profitability on an adjusted basis.

• Reaffirmed Positive Full Year 2026 Guidance

  Management reaffirmed its full year 2026 guidance, expecting revenues of $540 to $555 million, 33-35% growth in exome and genome revenue and volume, and positive adjusted net income.

auto_awesomeAnalysis

GeneDx Holdings Corp. delivered a robust financial performance for both the fourth quarter and full year 2025, consistently meeting or exceeding its own guidance across key metrics. The company demonstrated significant growth in its core exome and genome testing business, with full-year revenue increasing by 41% and exome/genome test revenue growing by 54% year-over-year. Notably, adjusted net income for the full year 2025 saw a substantial improvement to $41.8 million, up from $9.4 million in the prior year, signaling a positive trajectory towards profitability on an adjusted basis. The reaffirmation of strong 2026 guidance, including continued revenue and volume growth and positive adjusted net income, provides a clear and optimistic outlook for investors. Additionally, the company raised $21.1 million through an At-The-Market offering in Q4 2025, bolstering its cash position.